spot_img
Sunday, June 26, 2022
More
    HomeHealthA Roche Alzheimer's treatment fails to slow cognitive decline in patients

    A Roche Alzheimer’s treatment fails to slow cognitive decline in patients

    -



    Roche reported unfavorable outcomes Thursday from a long-running scientific trial investigating an experimental antibody remedy in individuals born with an inherited type of early onset Alzheimer’s illness.

    The Swiss pharma large has been working the Part 3 scientific trial for greater than a decade, aiming to indicate that an antibody known as crenezumab that targets poisonous mind plaques would possibly gradual and even stop Alzheimer’s illness in individuals born with a selected genetic mutation that usually causes cognitive impairment to start round age 44.

    Unlock this text by subscribing to STAT+ and revel in your first 30 days free!

    GET STARTED





    Source link

    Related articles

    Stay Connected

    0FansLike
    0FollowersFollow
    3,367FollowersFollow
    0SubscribersSubscribe
    spot_img

    Latest posts